By Dr. Daniel Karlsberg
A 39-year-old male came in for evaluation after a referral from a trusted friend. He had no active complaints, no known cardiovascular disease, and no reason to believe anything was wrong. Like many otherwise healthy individuals, he assumed that if there were a concern, he would feel it.
He didn’t.
Yet beneath that assumption, a significant and largely invisible risk had already begun to develop.
A Reassuring Picture at First Glance
At presentation, his clinical profile appeared largely unremarkable. He reported no symptoms and had no history of chronic disease management. His cardiac imaging, including a coronary artery calcium score, showed normal results. From a traditional standpoint, little suggested immediate concern.
A more comprehensive evaluation revealed a markedly different picture.
His low-density lipoprotein cholesterol measured greater than 240 mg/dL, nearly four times the optimal range. This level does not reflect lifestyle factors alone and raised immediate concern for an underlying genetic condition.
Further assessment pointed strongly toward familial hyperlipidemia, an inherited disorder that significantly increases the risk of premature atherosclerotic cardiovascular disease.
Additional findings included overweight body composition and a hemoglobin A1c in the prediabetic range. Together, these factors increased his long-term metabolic and cardiovascular risk.
The Disconnect Between Normal Imaging and Future Risk
This case highlights what imaging did not reveal.
His scan looked normal. His calcium score measured zero. No visible calcified plaque appeared.
His risk still remained high.
Familial hyperlipidemia accelerates atherosclerosis over time, often without symptoms and often without early imaging findings. Many individuals appear healthy for years until disease presents abruptly.
This gap between how a patient feels, what imaging shows, and what occurs biologically exposes a critical limitation in reactive care.
Cardiovascular disease does not begin when detection occurs. It develops long before.
A Shift From Observation to Action
The severity of his lipid elevation and overall risk profile required immediate action.
He started guideline-directed lipid-lowering therapy and received structured counseling focused on nutrition, weight reduction, and physical activity. He also entered a physician-led care model designed for continuous monitoring and adjustment over time.
Over the course of follow-up:
- LDL levels improved with therapy
- Body weight decreased steadily
- Glycemic markers moved in the right direction
- Lifestyle adherence strengthened through ongoing clinical support
This approach created consistency and turned short-term intervention into long-term risk management.
Why Early Detection Matters
Familial hyperlipidemia affects approximately 1 in 250 individuals, yet many cases remain undiagnosed. Many patients do not receive a diagnosis until later in life, often after cardiovascular disease develops.
This case reinforces several critical principles:
- Severe lipid abnormalities can exist without symptoms, even in younger adults
- Normal imaging does not eliminate future cardiovascular risk
- Early identification allows intervention before disease progression
- Longitudinal care supports sustained improvement and accountability
If this condition had gone unrecognized, his cardiovascular trajectory over the next decade would have looked very different.
Changing the Trajectory
This case centers on timing.
Intervention occurred before symptoms developed, before imaging changed, and before disease presented clinically.
That moment defines the true value of preventive medicine.
The most consequential risks often remain unseen, and the most meaningful outcomes come from identifying them early enough to change what happens next.
References
- Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285–e350.
- Nordestgaard BG, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population. European Heart Journal. 2013;34(45):3478–3490.
- Gidding SS, et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015;132(22):2167–2192.
- US Preventive Services Task Force. Screening for Lipid Disorders in Adults: Recommendation Statement. JAMA. 2016;316(19):1997–2007.
- Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. European Heart Journal. 2017;38(32):2459–2472.
American Diabetes Association. Standards of Medical Care in Diabetes—Prediabetes and Cardiovascular Risk. Diabetes Care. 2024.